CY1115856T1 - Μοναδα δοσολογιας περιεχουσα αναλογο προσταγλανδινης για την αγωγη της δυσκοιλιοτητας - Google Patents

Μοναδα δοσολογιας περιεχουσα αναλογο προσταγλανδινης για την αγωγη της δυσκοιλιοτητας

Info

Publication number
CY1115856T1
CY1115856T1 CY20141100997T CY141100997T CY1115856T1 CY 1115856 T1 CY1115856 T1 CY 1115856T1 CY 20141100997 T CY20141100997 T CY 20141100997T CY 141100997 T CY141100997 T CY 141100997T CY 1115856 T1 CY1115856 T1 CY 1115856T1
Authority
CY
Cyprus
Prior art keywords
dosage unit
prostaglendin
conscience
analog
protection
Prior art date
Application number
CY20141100997T
Other languages
English (en)
Inventor
Ryuji Ueno
Myra L Patchen
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115856(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of CY1115856T1 publication Critical patent/CY1115856T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Περιγράφεται μία μονάδα δοσολογίας για την αγωγή της δυσκοιλιότητας σε ασθενή άνθρωπο. Η μονάδα δοσολογίας της εφεύρεσης περιέχει ένα αλογονωμένο ανάλογο προσταγλανδίνης και ένα φαρμακευτικώς κατάλληλο έκδοχο. Η μονάδα δοσολογίας ανακουφίζει την δυσκοιλιότητα χωρίς ουσιώδεις παρενέργειες.
CY20141100997T 2001-11-14 2014-11-28 Μοναδα δοσολογιας περιεχουσα αναλογο προσταγλανδινης για την αγωγη της δυσκοιλιοτητας CY1115856T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14
EP10010211.0A EP2298314B1 (en) 2001-11-14 2002-11-14 Dosage unit comprising a prostaglandin analog for treating constipation

Publications (1)

Publication Number Publication Date
CY1115856T1 true CY1115856T1 (el) 2017-01-25

Family

ID=23293447

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100997T CY1115856T1 (el) 2001-11-14 2014-11-28 Μοναδα δοσολογιας περιεχουσα αναλογο προσταγλανδινης για την αγωγη της δυσκοιλιοτητας

Country Status (15)

Country Link
US (3) US8097653B2 (el)
EP (2) EP2298314B1 (el)
JP (2) JP4852229B2 (el)
AR (3) AR037524A1 (el)
AT (1) ATE522218T1 (el)
BR (1) BR0214075A (el)
CA (1) CA2464420C (el)
CY (1) CY1115856T1 (el)
DK (2) DK1443938T3 (el)
ES (2) ES2524369T3 (el)
HK (1) HK1155649A1 (el)
LU (1) LU92826I2 (el)
PT (2) PT2298314E (el)
TW (1) TWI331920B (el)
WO (1) WO2003041716A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
PT1562604E (pt) * 2002-10-23 2012-04-09 Sucampo Ag Compostos de prostaglandina para o tratamento de obesidade
CA2510051C (en) * 2002-12-27 2016-07-05 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP1871380B1 (en) * 2005-04-12 2011-10-19 Sucampo AG Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
BRPI0707333B8 (pt) * 2006-01-24 2021-05-25 R Tech Ueno Ltd composição farmacêutica que compreende um composto bicíclico, método de estabilização do composto bicíclico e formulação de cápsula de gelatina mole
US8026393B2 (en) * 2006-01-24 2011-09-27 Sucampo Ag Soft-gelatin capsule formulation
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
TW201118084A (en) * 2009-09-18 2011-06-01 Adolor Corp The use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
DE3873007T2 (de) * 1987-10-02 1992-12-03 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JPH0681728B2 (ja) 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2041417C (en) * 1990-05-01 2002-05-21 Ryuji Ueno Treatment of pancreatic disease with 15-keto-prostaglandin compounds
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
PH31171A (en) * 1992-02-04 1998-03-20 Esai Co Ltd Aminobenzonic acid derivatives useful for treatinggastrointestinal conditions.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
US6242485B1 (en) * 1996-06-10 2001-06-05 R-Tech Ueno Endothelin antagonist
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
ES2310013T3 (es) * 1997-11-28 2008-12-16 Sucampo Ag Uso de compuestos de 15-ceto-prostaglandina e como antagonistas de endotelina.
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
CZ303625B6 (cs) * 1999-10-15 2013-01-16 Sucampo Ag Stabilní farmaceutický prostredek obsahující bicyklickou slouceninu a acyglycerol, bicyklická sloucenina, zpusob stabilizace bicyklické slouceniny, farmaceutický prostredek obsahující bicyklickou slouceninu
ATE433754T1 (de) 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
CN1273140C (zh) 2001-05-18 2006-09-06 苏坎波公司 导泻组合物
WO2003030912A1 (en) 2001-08-31 2003-04-17 Sucampo Ag Prostaglandin analogs as chloride channel opener
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
CA2510051C (en) 2002-12-27 2016-07-05 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort

Also Published As

Publication number Publication date
TWI331920B (en) 2010-10-21
JP4852229B2 (ja) 2012-01-11
US8097653B2 (en) 2012-01-17
PT2298314E (pt) 2014-12-03
EP1443938A1 (en) 2004-08-11
CA2464420C (en) 2011-12-13
DK1443938T3 (da) 2011-09-26
US20130143958A1 (en) 2013-06-06
AR037524A1 (es) 2004-11-17
BR0214075A (pt) 2004-09-28
LU92826I2 (fr) 2015-11-24
DK2298314T3 (en) 2014-12-01
AR117404A2 (es) 2021-08-04
US20120088824A1 (en) 2012-04-12
ES2524369T3 (es) 2014-12-05
AR098997A2 (es) 2016-06-22
US8389542B2 (en) 2013-03-05
JP2005513014A (ja) 2005-05-12
HK1155649A1 (en) 2012-05-25
PT1443938E (pt) 2011-09-27
WO2003041716A1 (en) 2003-05-22
TW200300091A (en) 2003-05-16
US20030119898A1 (en) 2003-06-26
ES2368729T3 (es) 2011-11-21
JP2011201905A (ja) 2011-10-13
CA2464420A1 (en) 2003-05-22
ATE522218T1 (de) 2011-09-15
EP1443938B1 (en) 2011-08-31
EP2298314B1 (en) 2014-09-03
EP2298314A1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
CY1115856T1 (el) Μοναδα δοσολογιας περιεχουσα αναλογο προσταγλανδινης για την αγωγη της δυσκοιλιοτητας
ATE300306T1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
CY1118206T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη
DK1296633T3 (da) Medicinalproduktpakning til udryddelsesbehandling
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
CY1105834T1 (el) Χρηση παρασκευασματων για την εφαρμογη, στον κατω αναπνευστικο σωληνα αντισηπτικων παραγοντων και/ή παραγοντων που προαγουν την επουλωση των πληγων
MXPA05006670A (es) Administracion de capsaicinoides.
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
EA200601132A1 (ru) Предупреждение и лечение амилоидогенного заболевания
IS7431A (is) Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
DK1079857T3 (da) Meningitidis B/C-kombinationsvacciner
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
HK1068606A1 (en) Novel aminobenzoephenones
DE50101034D1 (de) Medizinischer oder dentalmedizinischer behandlungsstuhl
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
NO20021625L (no) Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog
RU2005131578A (ru) Аплидин для лечения множественной миеломы